Treatment of Leukemia and Lymphoma

New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology.

Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals, inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers.

The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future.

• Provides an up-to-date, state of the art discussion of a rapidly changing field
• Great breadth covering conventional chemotherapeutic agents, biologic agents such as antibodies, novel small molecule inhibitors and genetically engineered cells
• Written by international experts in each of the fields

Inhalt

Kinase Inhibitors in Leukemia
State of the Art Treatment of APL
Investigational Agents in Myeloid Disorders
Methodologic Issues in Investigation of Targeted Therapies in AML
Purine Analogues in Leukemia
Monoclonal Antibody Therapy in Lymphoid Leukemias
Native Antibody and Antibody-Targeted Chemotherapy for Acute Myeloid Leukemia
Radioimmunotherapy of Leukemia
Immunotoxins and Toxin Constructs in Leukemia/Lymphoma
Antibody Therapy of Lymphoma
Vaccines in Leukemia
Therapeutic Idiotype Vaccines for Non-Hodgkin's Lymphoma
Cytokine Modulation of the Innate Immune System in the Treatment of Leukemia and Lymphoma
Donor Lymphocyte Infusions
Somatic Cell Engineering and the Immunotherapy of Leukemias and Lymphomas